- Brands
- Offerings
- Diagnostic Panels
- Knowledge Center
- Diagnostics
Access on demand presentations led by subject matter experts and Abbott key opinion leaders to gain insight into industry trends, medical discoveries, healthcare technologies and much more.
Abbott is constantly searching for new ways to improve people's health. A critical success factor involves monitoring retroviruses and hepatitis viruses from around the globe with a surveillance program, to help ensure laboratory tests continue to accurately detect divergent viruses, regardless of where they are acquired. Since 1994, Abbott's Global Viral Surveillance Program has been at the forefront of viral surveillance continually evolving to impact the development of next generation solutions.
Hepatitis C is called a silent killer because it often goes unnoticed for decades until serious liver damage has occurred. Diagnosing infected individuals is the first step in preventing the spread of Hepatitis C to others, in linking patients to curative therapies, and in driving overall awareness.
A healthier future without Hepatitis C is now possible, through innovations in science and technology. Watch the educational webinar to learn how clinical laboratory advancements can help make elimination a reality.
The world health organization (WHO) published its first global health sector strategy on viral hepatitis in May 2016. The following year WHO reported that only about 20% of people with chronic Hepatitis C virus (HCV) were thought to be aware of their disease, and only a small fraction of those diagnosed are receiving treatment. WHO describes these and global Hepatitis B virus (HBV) estimates as “preliminary”. To remedy the situation, national governments need to do much more to meet their monitoring responsibilities in relation to viral hepatitis, a group of diseases that claims more lives annually than HIV or malaria do.
Without reliable information about the extent of the problem, and about the impact of interventions to mitigate the problem, it is not possible for health systems to determine how to best allocate their always-limited resources. Large knowledge gaps regarding disease epidemiology and intervention coverage may seem to be characteristic of resource-limited countries.
However, some of the most affluent countries in the world are unprepared to carry out the kind of evidence-based decision making that will be required to achieve the goal of eliminating viral hepatitis as a public health threat by 2030. This problem is partly reflective of how HCV infection manifests – often with a decades-long asymptomatic period during which liver deterioration progresses unnoticed. Yet monitoring the disease is not the greatest obstacle to progress against the global the epidemic. The greatest obstacle is government inaction, as reflected by the fact that globally less than half of all WHO member states report having viral hepatitis strategies or plans and only 12 are on track for elimination. Eliminating HCV as a public health threat is feasible – but only with greater attention to health systems. This presentation will review the main components of a people-centred health systems approach to viral hepatitis elimination.
In this webinar you will hear about a recently CE marked application for ARCHITECT STAT High Sensitive Troponin I, that aids in providing greater accuracy for estimation of risk for future cardiac events in apparently healthy people, when used in conjunction with clinical and diagnostics findings. Risk is classified as low, moderate or elevated and use of ARCHITECT STAT High Sensitive Troponin I, is supported by a large body of evidence. This simple blood test can aid in earlier intervention for high risk patients and may avoid unnecessary tests and treatments in low risk patients. ARCHITECT STAT High Sensitive Troponin I, is well known to many through its use in Emergency Departments where it has been trusted for many years to rule in or rule out Myocardial Infarction. This latest application sets the stage to support tackling the cardiovascular disease burden through prevention.
In this webinar you can learn more about how the emerging role of cardiac biomarkers in cardiac risk stratification and how taking a patient centric approach through the additional use of high-sensitivity troponin I, in conjunction with other clinical diagnostic findings, can guide treatment and to help improve patient outcomes.
Build key laboratory competencies and explore topics from various disciplines with our learning guides.
Find the latest information in laboratory science, therapeutic areas and Abbott innovation.
Watch the webinar to hear from experts how you can realize the value within and beyond your laboratory walls with a TVO approach.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.